Comparison · NCT02073682-fe1bfa96
Edoxaban Group vs Dalteparin Group: Number of Participants With VTE-Related Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Edoxaban Group vs Dalteparin Group: Number of Participants With VTE-Related Death. Trial comparisons, record NCT02073682-fe1bfa96. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02073682-fe1bfa96
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0115 | 0.00528 | 0.0248 | wilson | |
| Risk in group 2 | 0.00763 | 0.00297 | 0.0195 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00386 | -0.0095 | 0.018 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.51 | 0.427 | 5.3 | log | |
| Odds ratio, group 1 over group 2 | 1.51 | 0.424 | 5.39 | log | |
| Number needed to treat, for one more participant with the outcome on Edoxaban Group than on Dalteparin Group | 259 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Edoxaban Group | After 5 days of low molecular weight heparin (LMWH), participants received edoxaban treatment daily | 6 | 522 | OG000 |
| Group 2 | Dalteparin Group | Participants received dalteparin daily | 4 | 524 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With VTE-Related Death
- Description
- Time frame
- 12 months
- Population
- mITT (Safety Analysis Set)
Source ClinicalTrials.gov
Trial
- Title
- Cancer Venous Thromboembolism (VTE)
- NCT number
- NCT02073682
- Phases
- PHASE3
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
- Interventions
- Edoxaban, Dalteparin, Low molecular weight heparin
- Lead sponsor
- Daiichi Sankyo
- Results first posted
- 2018-10-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02073682?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02073682-fe1bfa96